Ch 19 P 4 Pharmacist

Question 1

A year

Answer 1

Begins with the first day of the pharmacist’s birth month and ends the last day of the pharmacist’s birth month the following year

Question 2

Activity

Answer 2

As used in the ACPE criteria for quality and these regulations, the term refers to an individual educational experience or program such as a lecture, home study course, workshop, seminar, symposium, etc.

Question 3

Alternative supervising physician

Answer 3

A physician who holds a current unrestricted license, is a cosignatory on the notification of supervision, agrees to act as the supervising physician in the supervising physician’s absence, or expand the “scope of practice or sites of practice” of the pharmacist’ clinician and is approved by the board.

Question 4

Approved provider

Answer 4

An institution, organization, or agency that has been recognized by the ACPE as having met its criteria indicative of the ability to provide quality continuing pharmaceutical education, and is listed in the ACPE annual publication of approved providers.

Question 5

Board

Answer 5

The NM Board of Pharmacy

Question 6

Consultation

Answer 6

Communication in person, telephonically, by two-way radio, by email or by other electronic means.

Question 7

Contact hour

Answer 7

A unit of measure equivalent to 60 minutes of participation in an approved organized learning experience or activity.

Question 8

Continuing education unit (CEU)

Answer 8

Ten contact hours of participation or it’s equivalent in an organized continuing education activity sponsored by an approved provider.

Question 9

Continuing pharmacy education (CPE)

Answer 9

A structured education activity offered by an approved provider, designed or intended to support the continuing development of pharmacies or pharmacy technicians to maintain and enhance their competence. Continuing pharmacy education should promote problem-solving and critical thinking and be applicable to the practice of pharmacy.

Question 10

Continuing professional development (CPD)

Answer 10

the responsibility of individual pharmacists for systematic maintenance, development, and broadening of knowledge, skills, and attitudes, to ensure continuing competence as a professional, throughout their careers.

Question 11

Criteria for quality

Answer 11

Continuing education provider shall show evidence of adherence to the criteria adopted by the ACPE as indicative of the ability to provide continuing pharmaceutical education activities; areas include administrative and organization, budget and resources, teaching staff, educational content management of activity, method of delivery, facilities, evaluation mechanism.

Question 12

Dangerous drug

Answer 12

A drug that because of any potentiality for harmful effect or the methods of its use or the collateral measures necessary to its use, is not safe except under the supervision of a physician licensed by law to direct the use of such drug and the drug prior to dispensing is required by federal law and state law to bear the manufacturer’s legend “Caution: Federal law prohibits dispensing without a prescription.”

Question 13

Guidelines or protocol

Answer 13

A written agreement between a pharmacist clinician or group of pharmacist clinicians and a physician or group of physicians that delegates prescriptive authority.

Question 14

Initial pharmacist licensure

Answer 14

The license issued shall be valid for no less than 24 months. The license will expire the last date of his/her birth month that immediately follows the minimum 24 month time period.

Question 15

Live programs

Answer 15

CPE activities that provide for direct interaction between faculty and participants and may include lectures, symposia, live teleconferences, workshops, etc.

Question 16

Mediated forms

Answer 16

Learning transmitted via an intermediate mechanism such as audio and visual tape, telephonic transmission, etc.

Question 17

Monitor dangerous drug therapy

Answer 17

Review the dangerous drug therapy regiment of patients by a pharmacist clinician for the purpose of evaluating and rendering advice to the prescribing physician regarding adjustment of the regimen. “Monitor dangerous drug therapy” includes:

(1) collecting and reviewing patient dangerous drug histories
(2) measuring and reviewing routine patient vital signs including pulse, temperature, blood pressure, and respiration
(3) ordering and evaluating the results of laboratory tests relating to dangerous drug therapy, including blood chemistries and cell counts, controlled substance therapy levels, blood, urine, tissue or other body fluids, culture and sensitivity tests when performed in accordance with guidelines or protocols applicable to the practice setting and
(4) evaluating situations that require the immediate attention of the physician and instituting or modifying treatment procedures when necessary.

Question 18

Oversight committee

Answer 18

A joint committee made up of four members to hear issues regarding pharmacist clinicians’ prescriptive authority activities and supervising physicians’ direction of these activities.

Question 19

Patient safety

Answer 19

The prevention of healthcare errors and the elimination or mitigation of patient injury caused by healthcare errors.

Question 20

Pharmaceutical care

Answer 20

The provision of drug therapy and other patient care services related to drug therapy intended to achieve definite outcomes that improve a patient’s quality of life, including identifying potential and actual drug-related problems, resolving actual drug-related problems and preventing potential drug-related problems.

Question 21

Pharmacist

Answer 21

A person duly licensed by the board to engage in the practice of pharmacy pursuant to the pharmacy act.

Question 22

Pharmacist Clinician

Answer 22

A pharmacist with additional training required by regulations adopted by the board in consultation with the New Mexico medical board and the New Mexico academy of physician assistants, who exercise prescriptive authority in accordance with guidelines or protocol.

Question 23

Pharmacist in charge

Answer 23

Pharmacist who accepts responsibility for the operation of a pharmacy in conformance with all laws and rules pertinent to the practice of pharmacy and the distribution of drugs who is personally in full and actual charge of the pharmacy and its personnel.

Question 24

Practice of pharmacy

Answer 24

Continually optimizing medication safety, patient wellness, and quality of services through the effective use of pharmaceutical care and emerging technologies and competency-based and performance-based training.

(1) Pharmaceutical dispensing including product selection. Practice of pharmacy may include, but is not limited to:
(2) Specialty pharmacy practice including pharmacists working for licensed pharmaceutical manufacturers or wholesalers;
(3) Practice of telepharmacy within and across state lines;
(4) Engaging in health care educational activities;
(5) Pharmacy-specific academia;
(6) Provision of those acts or services necessary to provide pharmaceutical care in all areas of patient care including patient counseling, prescriptive authority, drug administration, primary care, medication therapy management, collaborative practice, and monitoring dangerous drug therapy;
(7) Inspecting on a full time basis to ensure compliance with the practice of pharmacy;
(8) Provision of pharmaceutical and drug information services, as well as consultant pharmacy services;
(9) Engaging in other phases of the pharmaceutical profession including those with research or investigational or dangerous drugs; or
(10) Engaging in functions that relate directly to the administrative, advisory, or executive responsibilities pursuant to the practice of pharmacy in this state;
(11) The responsibility for compounding and labeling of drugs and devices;
(12) The proper and safe storage of drugs and devices
(13) The maintenance of proper records.

Question 25

Practitioner

Answer 25

A physician duly authorized by law in New Mexico to prescribe dangerous drugs including controlled substances in schedules II through V.

Question 26

Prescriptive authority

Answer 26

The authority to prescribe, administer, monitor or modify dangerous drug therapy.

Question 27

Professional judgment

Answer 27

A cognitive process, by a licensed pharmacist, that takes education, experience, and current standards of practice into consideration when drawing conclusions and reaching decisions.

Question 28

Renewal period

Answer 28

Continuing education programs or activities must be completed during the 24 month time period occurring between the first day of the pharmacist’s birth month and the last day of his/her birth month 2 years later.

Question 29

Scope of practice

Answer 29

Those duties and limitations of duties placed upon a pharmacist clinician and/or the alternate supervising physician(s) and the board; includes the limitations implied by the field of practice of the supervising physician and/or the alternate supervising physician(s) and the board.

Question 30

Supervising physician

Answer 30

A doctor, or group of doctors, of medicine or osteopathy approved by the respective board to supervise a pharmacist clinician; “supervising physician includes a physician approved by the respective board as an alternate supervising physician.”